On the public citation graph
Positioning sulphonylureas in a modern treatment algorithm for patients with type 2 diabetes: Expert opinion from a European consensus panel
0 signed · 72 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jama.2018.18269openalex-snapshot
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
inferredcites →https://doi.org/10.1007/s11892-014-0473-5openalex-snapshot
Sulfonylureas: A New Look at Old Therapy
inferredcites →https://doi.org/10.1016/j.amepre.2013.04.017openalex-snapshot
Lifetime Direct Medical Costs of Treating Type 2 Diabetes and Diabetic Complications
inferredcites →https://doi.org/10.1016/j.diabres.2019.02.014openalex-snapshot
Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure
inferredcites →https://doi.org/10.1016/j.diabres.2019.107785openalex-snapshot
The future of new drugs for diabetes management
inferredcites →https://doi.org/10.1016/j.diabres.2019.107836openalex-snapshot
The right place for Sulphonylureas today: Part of ‘Review the Series: Implications of recent CVOTs in Type 2 diabetes mellitus’
inferredcites →https://doi.org/10.1016/j.ecl.2017.10.002openalex-snapshot
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes Mellitus
inferredcites →https://doi.org/10.1016/j.jacc.2018.07.071openalex-snapshot
The Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction
inferredcites →https://doi.org/10.1016/j.pcd.2019.01.003openalex-snapshot
Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs
inferredcites →https://doi.org/10.1016/s0140-6736(18)32590-xopenalex-snapshot
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
inferredcites →https://doi.org/10.1016/s0140-6736(18)32840-xopenalex-snapshot
Real-world studies no substitute for RCTs in establishing efficacy
inferredcites →https://doi.org/10.1016/s0140-6736(19)31149-3openalex-snapshot
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
inferredcites →https://doi.org/10.1016/s0300-7073(12)70593-5openalex-snapshot
Management of Hyperglycemia in Type 2 Diabetes
inferredcites →https://doi.org/10.1016/s2213-8587(17)30317-0openalex-snapshot
Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial
inferredcites →https://doi.org/10.1016/s2213-8587(18)30025-1openalex-snapshot
Do sulphonylureas still have a place in clinical practice?
inferredcites →https://doi.org/10.1016/s2213-8587(20)30038-3openalex-snapshot
Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials
inferredcites →https://doi.org/10.1056/nejmoa0802987openalex-snapshot
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
inferredcites →https://doi.org/10.1056/nejmoa1811744openalex-snapshot
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
inferredcites →https://doi.org/10.1080/00325481.2019.1578590openalex-snapshot
Management of hypoglycemia in older adults with type 2 diabetes
inferredcites →https://doi.org/10.1093/eurheartj/ehv301openalex-snapshot
Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database
inferredcites →https://doi.org/10.1111/dom.12306openalex-snapshot
Combination therapy with metformin plus sulphonylureas versus metformin plus DPP ‐4 inhibitors: association with major adverse cardiovascular events and all‐cause mortality
inferredcites →https://doi.org/10.1111/dom.12314openalex-snapshot
Cardiovascular safety of combination therapies with incretin‐based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus – a retrospective nationwide study
inferredcites →https://doi.org/10.1111/dom.13710openalex-snapshot
Real‐world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network
inferredcites →https://doi.org/10.1111/dom.13962openalex-snapshot
Enrolment criteria for diabetes cardiovascular outcome trials do not inform on generalizability to clinical practice: The case of glucagon‐like peptide‐1 receptor agonists
inferredcites →https://doi.org/10.1111/j.1365-2362.2004.01381.xopenalex-snapshot
GUIDE study: double‐blind comparison of once‐daily gliclazide MR and glimepiride in type 2 diabetic patients
inferredcites →https://doi.org/10.1111/jgs.15767openalex-snapshot
American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults
inferredcites →https://doi.org/10.1136/bmj.b4731openalex-snapshot
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database
inferredcites →https://doi.org/10.1136/bmj.i3625openalex-snapshot
Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study
inferredcites →https://doi.org/10.1136/bmjdrc-2018-000627openalex-snapshot
Eligibility of patients with type 2 diabetes for sodium–glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study
inferredcites →https://doi.org/10.1161/circresaha.115.306884openalex-snapshot
Vascular Complications of Diabetes
inferredcites →https://doi.org/10.1177/1479164113490765openalex-snapshot
Individualized glycaemic targets and pharmacotherapy in type 2 diabetes
inferredcites →https://doi.org/10.1186/s12933-017-0574-yopenalex-snapshot
Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes
inferredcites →https://doi.org/10.1371/journal.pone.0082880openalex-snapshot
Safety and Efficacy of Gliclazide as Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Trials
inferredcites →https://doi.org/10.2337/dc08-0167openalex-snapshot
Is the Combination of Sulfonylureas and Metformin Associated With an Increased Risk of Cardiovascular Disease or All-Cause Mortality?
inferredcites →https://doi.org/10.2337/dc17-0595openalex-snapshot
Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events
inferredcites →https://doi.org/10.2337/dc19-s010openalex-snapshot
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2019
inferredcites →https://doi.org/10.2337/dc20-s009openalex-snapshot
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
inferredcites →https://doi.org/10.2337/dc20-s010openalex-snapshot
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020
inferredcites →https://doi.org/10.2337/dci18-0012openalex-snapshot
The Cost of Diabetes Care—An Elephant in the Room
inferredcites →https://doi.org/10.2337/dci18-0033openalex-snapshot
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
inferredcites →https://doi.org/10.2337/dci19-0034openalex-snapshot
A Verdict for Glimepiride: Effective and Not Guilty of Cardiovascular Harm
inferredcites →https://doi.org/10.2337/dci19-0066openalex-snapshot
2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
inferredcites →https://doi.org/10.2337/diacare.12.3.203openalex-snapshot
Symptomatic Hypoglycemia in NIDDM Patients Treated With Oral Hypoglycemic Agents
inferredcites →https://doi.org/10.2337/diaspect.27.2.82openalex-snapshot
A Brief History of the Development of Diabetes Medications
inferredcites →https://doi.org/10.4103/ijem.ijem_556_17openalex-snapshot
Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of Type 2 diabetes mellitus – International Task Force
inferredcites →https://doi.org/10.4158/cs-2018-0535openalex-snapshot
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2019 Executive Summary
inferredcites →https://doi.org/10.4158/ep151126.csopenalex-snapshot
Consensus Statement By The American Association Of Clinical Endocrinologists And American College Of Endocrinology On The Comprehensive Type 2 Diabetes Management Algorithm – 2016 EXECUTIVE SUMMARY
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4765193openalex-extracted
Synergistic Effects of Sulfonylureas with Chemotherapeutics: In Vitro Screening Reveals Enhanced Cytotoxicity of Doxorubicin in Combination with Sulfonylureas
inferred← citeshttps://doi.org/10.1002/mco2.70588openalex-snapshot
Loss of Beta‐Cell Identity and Function as a Mechanism of Secondary Failure of Sulfonylurea Therapy in Diabetes
inferred← citeshttps://doi.org/10.1007/s11428-021-00822-zopenalex-snapshot
Diabetestherapie bei fortgeschrittenen Lebererkrankungen und Leberzirrhose
inferred← citeshttps://doi.org/10.1007/s13300-021-01137-4openalex-snapshot
Identification of the Inappropriate Clinical Actions (DON'T) to Improve the Management of Patients with Type 2 Diabetes Failing Basal Insulin Supported Oral Treatment: Results of Survey for a Panel of Diabetes Specialists in Italy
inferred← citeshttps://doi.org/10.1007/s42000-025-00734-3openalex-snapshot
Current treatment for diabetes: a holistic approach
inferred← citeshttps://doi.org/10.1016/j.deman.2021.100002openalex-snapshot
Sulphonylureas in the management of type 2 diabetes: To be or not to be?
inferred← citeshttps://doi.org/10.1016/j.ijbiomac.2022.11.038openalex-snapshot
An investigation into the potential action of polyphenols against human Islet Amyloid Polypeptide aggregation in type 2 diabetes
inferred← citeshttps://doi.org/10.1016/j.mmm.2020.11.001openalex-snapshot
Existe-t-il encore une place pour les sulfamides hypoglycémiants dans le traitement du diabète de type 2 en 2021 ?
inferred← citeshttps://doi.org/10.1016/j.numecd.2021.06.006openalex-snapshot
Initial treatment of diabetes in Italy. A nationwide population-based study from of the ARNO Diabetes Observatory
inferred← citeshttps://doi.org/10.1080/14656566.2021.1909570openalex-snapshot
Considerations for single- versus multiple-drug pharmacotherapy in the management of painful diabetic neuropathy
inferred← citeshttps://doi.org/10.1080/14656566.2021.1999413openalex-snapshot
The role of sulfonylureas in the treatment of type 2 diabetes
inferred← citeshttps://doi.org/10.1080/14656566.2022.2141108openalex-snapshot
Evaluating gliclazide for the treatment of type 2 diabetes mellitus
inferred← citeshttps://doi.org/10.1111/dom.14675openalex-snapshot
Preventing all‐cause hospitalizations in type 2 diabetes with sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide ‐1 receptor agonists: A narrative review and proposed clinical approach
inferred← citeshttps://doi.org/10.1111/dom.16632openalex-snapshot
Loss of β‐cell identity in human islets treated with glibenclamide
inferred← citeshttps://doi.org/10.1177/11795514221074663openalex-snapshot
Position of Sulfonylureas in the Current ERA: Review of National and International Guidelines
inferred← citeshttps://doi.org/10.1186/s12933-022-01600-xopenalex-snapshot
Time-resolved trajectory of glucose lowering medications and cardiovascular outcomes in type 2 diabetes: a recurrent neural network analysis
inferred← citeshttps://doi.org/10.1210/clinem/dgab849openalex-snapshot
New Horizons: Next-Generation Insulin Analogues: Structural Principles and Clinical Goals
inferred← citeshttps://doi.org/10.18203/2349-3933.ijam20220442openalex-snapshot
Utility and benefits of sulfonylureas beyond glycemic control
inferred← citeshttps://doi.org/10.2147/dmso.s390075openalex-snapshot
Efficacy of Dapagliflozin in Southern Europe Across the Spectrum of Characteristics of Type 2 Diabetes: An International Real-World Analysis
inferred← citeshttps://doi.org/10.24121/dh.2022.23openalex-snapshot
A 2-es típusú diabetes mellitus antihiperglikémiás kezelésének változása Magyarországon 2015–2020 között – adatbáziselemzés országos adatai
inferred← citeshttps://doi.org/10.3390/ijms26062770openalex-snapshot
Unraveling the Mystery of Insulin Resistance: From Principle Mechanistic Insights and Consequences to Therapeutic Interventions
inferred← citeshttps://doi.org/10.3390/medicina58101382openalex-snapshot
Changing Patterns of Antihyperglycaemic Treatment among Patients with Type 2 Diabetes in Hungary between 2015 and 2020—Nationwide Data from a Register-Based Analysis
inferred← citeshttps://doi.org/10.3390/pharmaceutics17060777openalex-snapshot
Revolutionizing Diabetes Management Through Nanotechnology-Driven Smart Systems
inferred← citeshttps://doi.org/10.36290/vnl.2025.026openalex-snapshot
Treatment of type 2 diabetes mellitus - a current view of the different drug classes and strategies for their use
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.